The Alpha-1 Study is a clinical research study currently enrolling individuals 18 to 78 (inclusive) with Alpha-1 Antitrypsin Deficiency.
The purpose of this study is to evaluate the safety, tolerability, and effectiveness of an investigational medication in individuals with Alpha-1 Antitrypsin Deficiency.
Interested individuals will be evaluated during a screening period to determine their eligibility to participate. Your participation could last approximately 11–16 weeks depending on whether or not you have ever been on augmentation therapy.
Those who qualify will receive all study-related medications and procedures at no cost.
You and your study doctor may choose to have some of the study visits at your home with a home health nurse, allowing for a reduced number of times that you must travel to the study site.
You may also be compensated financially for your study-related time and travel.
Condition | Alpha 1 Antitrypsin Deficiency |
---|---|
Clinical Study Identifier | TX232161 |
Last Modified on | 23 November 2020 |
,
You have contacted , on
Your message has been sent to the study team at ,
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreEvery year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer
Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!
No annotations made yet
Congrats! You have your own personal workspace now.